Compare AMTB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | GERN |
|---|---|---|
| Founded | 1979 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 821.1M |
| IPO Year | 2018 | N/A |
| Metric | AMTB | GERN |
|---|---|---|
| Price | $22.51 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $23.67 | $2.17 |
| AVG Volume (30 Days) | 190.5K | ★ 14.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.29 | $26.91 |
| Revenue Next Year | $7.67 | $43.75 |
| P/E Ratio | $51.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.62 | $1.04 |
| 52 Week High | $24.38 | $2.01 |
| Indicator | AMTB | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 32.94 |
| Support Level | $21.98 | $1.24 |
| Resistance Level | $22.75 | $1.29 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 49.13 | 10.42 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.